NCT04618744 - A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

June 27, 2022

Study Completion Date

June 27, 2022

Conditions

Diabetes Mellitus, Type 2NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

ORMD-0801 (Insulin) capsule 8 mg BD

8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.

OTHER

Placebo

Matching Placebo

Trial Locations (3)

Orange County Research Center, Tustin

Tel Aviv Sourasky Medical Center- Ichilov Hospital, Tel Aviv

Hadassah Medical Center, Jerusalem